FIRST AMENDMENT TO SUPPLY AGREEMENTSupply Agreement • March 31st, 2023 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT to the Supply Agreement dated February 28, 2018 (this “First Amendment”) is effective as of December 6, 2019 (the “First Amendment Effective Date”), and is by and between Spectrum Pharmaceuticals, Inc. (“Spectrum”) and Hanmi Pharmaceutical Co., Ltd. (“Hanmi”). Spectrum and Hanmi may each be referred to individually herein as a “Party,” and collectively as the “Parties.”
SUPPLY AGREEMENTSupply Agreement • March 31st, 2023 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This Supply Agreement (the “Agreement”) is entered into as of February 28, 2018 (the “Effective Date”) by and between Spectrum Pharmaceuticals Inc., a Delaware corporation (“Spectrum”) and Hanmi Pharmaceuticals Co., Ltd., a company incorporated under the laws of the Republic of Korea (“Hanmi”). In this Agreement, Hanmi and Spectrum each may be referred to individually as a “Party” and together as “Parties.”
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 31st, 2023 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO THE LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT (this “First Amendment”) is made and effective as of February 28, 2018 (the “First Amendment Effective Date”) by and between Spectrum Pharmaceuticals Inc., a Delaware corporation (“Spectrum”) and Hanmi Pharmaceuticals Co., Ltd., a company incorporated under the laws of the Republic of Korea (“Hanmi”). In this First Amendment, Hanmi and Spectrum each may be referred to individually as a “Party” and together as the “Parties.”
LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTLicense, Development and Supply Agreement • March 31st, 2023 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This License, Development and Supply Agreement (the “Agreement”) is entered into as of October 8, 2014 (the “Effective Date”) by and between Spectrum Pharmaceuticals inc., a Delaware corporation (“Spectrum”) and Hanmi Pharmaceuticals Co., Ltd., a company incorporated under the laws of the Republic of Korea (“Hanmi”).
SECOND AMENDMENT TO LICENSE AGREEMENT - ROLONTISLicense Agreement • March 31st, 2023 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This SECOND AMENDMENT TO LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT - ROLONTIS (this “Second Amendment”) is made and effective as of January 1st, 2022 (the “Second Amendment Effective Date”) by and between Spectrum Pharmaceuticals Inc., a Delaware corporation (“Spectrum”) and Hanmi Pharmaceuticals Co., Ltd., a company incorporated under the laws of the Republic of Korea (“Hanmi”). In this Second Amendment, Hanmi and Spectrum each may be referred to individually as a “Party” and together as the “Parties.”
SECOND AMENDMENT TO SUPPLY AGREEMENT -ROLONTISSupply Agreement • March 31st, 2023 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This SECOND AMENDMENT TO SUPPLY AGREEMENT - ROLONTIS (this “Second Amendment”) is made and effective as of January 1st, 2022 (the “Second Amendment Effective Date”) by and between Spectrum Pharmaceuticals Inc., a Delaware corporation (“Spectrum”) and Hanmi Pharmaceuticals Co., Ltd., a company incorporated under the laws of the Republic of Korea (“Hanmi”). In this Second Amendment, Hanmi and Spectrum each may be referred to individually as a “Party” and together as the “Parties.”
